Scientists (including Mark Wilkinson from the University of Sheffield’s Healthy Lifespan Institute and Department of Oncology and Metabolism) have identified new genetic risk factors for osteoarthritis, which could now be treated with licensed drugs repurposed to target the debilitating condition. Click here to see the full article.
Can bone mineral density be used as a surrogate for fracture risk reduction in trials of osteoporosis drugs? Richard Eastell & colleagues have US government funding to conduct an individual-patient analysis. Click here for more details.
A pioneering study, led by Professor Mark Wilkinson from the University of Sheffield’s Department of Oncology and Metabolism in partnership with Sheffield Teaching Hospitals NHS Foundation Trust, found a drug already used to treat osteoporosis, called denosumab, could help to protect the bone from being attacked and prevent the need for some repeat hip replacement operations.
Click here to see the full article.
Dr Syazrah Salam, an Honorary Clinical Fellow in the Department of Oncology and Metabolism, has been invited to give the 2020 Yorkshire Turner Warwick Lecture. The Turner Warwick Lecture is awarded by the Royal College of Physicians to clinical trainees to showcase their research or quality improvement projects. Her lecture will focus on the diagnostic accuracy of non-invasive tests, such as biomarkers and high resolution bone imaging, as replacement for bone biopsy to diagnose renal osteodystrophy. The lecture will be delivered online via the RCP Player on Friday 6 November.
“The Genetic Epidemiology of Joint Shape and the Development of Osteoarthritis” by Mark Wilkinson and Eleftheria Zeggini
In this review from the University of Sheffield and the Helmholtz Institute in Munich, we review the genetics that underpin how joint shape develops. We also explore how this can influence an individual’s risk of developing osteoarthritis, one of the world’s most common, chronic conditions.
Click here to read the full article.
Arthritis drugs could be repurposed to help prevent breasts cancer spreading to the bone according to new study
- New research from the University of Sheffield uncovers role of protein released by bone marrow in spread of breast cancer to the bone
- Drugs that can block the action of the protein are already in use by the NHS to treat arthritis
- Breast cancer is the UK’s most common cancer and around 11,500 women still lose their lives each year in the UK
Click here to read the full article
Gwendolyn Bridges (1925-2016), a well-loved local Sheffield resident, has left a very generous legacy gift to support the Mellanby Centre for Bone Research. Please click here for further details.
Dr Meena Balasubramanian was a member of the Faculty at the 4th International Diabetes and International Conference – DECON 2018, on 14th and 15th April, Coimbatore, India
Dr Meena Balasubramanian co-presented the BOND ERN White Paper in the European Parliament, Brussels, on 28 February 2018 .
Sarcoma Research Unit, a new European Research Laboratory in the Mellanby Centre
The “Sarcoma Research Unit”, a European associated Laboratory on the pathogenesis of sarcomas has been created for 4 years (2016-2020) at the interface between the University of Sheffield, INSERM (French national research institute of health and medical research) and the University of Nantes (Professor F. Gouin, France). This research laboratory headed by Professor Dominique Heymann aims to characterize the tumour microenvironment, its role in the control of cancer cell dormancy/proliferation and metastatic process for the identification of new therapeutic targets and development of new therapies. The project is more specifically focused on the analysis of tumour heterogeneity at the single cell level. This new European Associated Laboratory will contribute to the international visibility of the Mellanby Centre and will strengthen the international recognition of both groups in the field of bone sarcoma.
13 August 2016
Predicting human movements
Smart multiscale models of human joints and muscles are being developed by bioengineers in the Insigneo Institute for in silico Medicine, which will give clinicians the power to assess the risk of bone fractures in patients with osteoporosis and help predict the onset and development of Parkinson’s disease.
2 August 2016
Statement from the IOF based on a paper published by Professor Richard Eastell et al. on bone turnover markers.